Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 06996 ANTENGENE-B > Detailed Quotes

06996 ANTENGENE-B

Watchlist
4.530
+0.430+10.49%
Trading Session 12/05 15:26 CCT
High
4.680
Open
4.180
Turnover
15.10M
Low
4.140
Pre Close
4.100
Volume
3.48M
Market Cap
3.06B
P/E(TTM)
Loss
52wk High
11.120
Shares
674.89M
P/E(Static)
Loss
52wk Low
2.890
Float Cap
3.06B
Bid/Ask %
83.58%
Historical High
22.500
Shs Float
674.89M
Volume Ratio
3.79
Historical Low
2.890
Dividend TTM
--
Div Yield TTM
--
P/B
1.18
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.52%
Amplitude
13.17%
Avg Price
4.341
Lot Size
500
Float Cap
3.06B
Bid/Ask %
83.58%
Historical High
22.500
Shs Float
674.89M
Volume Ratio
3.79
Historical Low
2.890
Dividend TTM
--
P/B
1.18
Dividend LFY
--
Turnover Ratio
0.52%
Amplitude
13.17%
Avg Price
4.341
Lot Size
500
Price Forecast

No Data

News

Comment

Company Overview More
Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards. Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other. Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.
CEO: Jianming Mei
Market: Hong Kong motherboard
Listing Date: 11/20/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist